| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 16,500 | 17,100 | 11:46 | |
| 16,600 | 17,000 | 10:01 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | SI-BONE receives FDA clearance for spinal fusion system | 1 | Investing.com | ||
| 28.09. | SI-BONE, Inc.: SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx, Extending Its Compromised Bone Franchise Beyond the Pelvis | 160 | GlobeNewswire (Europe) | SANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised... ► Artikel lesen | |
| 11.09. | SI-BONE, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.08. | SI-BONE, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | SI-BONE signals 2026 revenue of $231M-$233M as it plans Q4 launch of third breakthrough device | 4 | Seeking Alpha | ||
| 04.08. | SI-BONE Q2 2026 slides: revenue up 15%, shares fall on outlook | 5 | Investing.com | ||
| 03.08. | Earnings Call Transkript: SI-BONE übertrifft Q2-Prognosen, Aktie bricht nachbörslich dennoch ein | 2 | Investing.com Deutsch | ||
| SI-BONE Aktie jetzt für 0€ handeln | |||||
| 03.08. | SI-BONE GAAP EPS of -$0.09 beats by $0.06, revenue of $56M beats by $0.6M | 2 | Seeking Alpha | ||
| 03.08. | SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance | 217 | GlobeNewswire (Europe) | Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period)... ► Artikel lesen | |
| 03.08. | SI-BONE, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.07. | SI-BONE, Inc.: SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026 | 2 | GlobeNewswire (USA) | ||
| 08.06. | SI-BONE, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.06. | Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now | 13 | Zacks | ||
| 01.06. | Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know | 10 | Zacks | ||
| 15.05. | How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27% | 1 | Zacks | ||
| 13.05. | Why Si-Bone Stock Soared by Almost 20% on Tuesday | 9 | The Motley Fool | ||
| 12.05. | SI-BONE targets $230M-$233M 2026 revenue while CMS proposes new DRGs that could add up to $50,000 per Granite procedure | 3 | Seeking Alpha | ||
| 12.05. | Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates | 13 | Zacks | ||
| 12.05. | SI-BONE Q1 2026 slides: profitability surges, physician base expands | 2 | Investing.com | ||
| 11.05. | SI-BONE GAAP EPS of -$0.10 beats by $0.09, revenue of $52.59M beats by $1.43M | 1 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 12,380 | +1,81 % | BRANDMELDUNG bei Eckert&Ziegler: Diese brandneue Prognose ändert einfach alles - Mein Rat: sofort handeln! | ||
| DRAEGERWERK | 114,00 | +2,33 % | Draegerwerk AG & Co. KGaA: Sechsjähriger FDA-Belastungsfaktor beseitigt; US-Monitoring-Geschäft rückt wieder in den Fokus; KAUFEN | Dräger hat ein sechs Jahre währendes regulatorisches Kapitel im US-Patientenmonitoring endlich abgeschlossen. Nach der FDA-Freigabe (Clearance) von Dräger IACS VG8.1 hat die Behörde den 2020 ausgesprochenen... ► Artikel lesen | |
| MEDTRONIC | 77,80 | -0,56 % | Zwei Dividendenwerte im Crash-Rabatt: Warum Cisco und Medtronic jetzt ins Visier konservativer Anleger rücken | Der jüngste Kursrückgang an den Aktienmärkten eröffnet nach Einschätzung eines Beitrags auf Seeking Alpha selektive Einstiegsgelegenheiten bei dividendenstarken Blue Chips. Im Fokus stehen Cisco Systems... ► Artikel lesen | |
| THERMO FISHER | 579,80 | -0,24 % | Thermo Fisher Scientific: Strategische Neuausrichtung und Margenwachstum! | ||
| TELADOC HEALTH | 4,879 | -1,15 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| HIMS & HERS HEALTH | 25,380 | +1,44 % | Truist reiterates Hold on Hims and Hers stock, $32 target | ||
| SERNOVA BIOTHERAPEUTICS | 0,070 | -4,88 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 37,710 | +0,61 % | Boston Scientific Names Fitzgerald Executive Vice President & COO In New Operating Restructure | WASHINGTON (dpa-AFX) - Boston Scientific Corp. (BSX), a medical technology company, on Wednesday announced that it has appointed Joseph M. Fitzgerald as Executive Vice President and Chief Operating... ► Artikel lesen | |
| GERATHERM MEDICAL | 2,060 | +4,30 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| DEXCOM | 75,00 | -0,53 % | Medtech-Branche: Citi bestätigt Abbott und Dexcom als Top-Picks | ||
| PAUL HARTMANN | 195,00 | -0,26 % | Januar bis Juni 2026: PAUL HARTMANN steigert erneut Umsatz und Ergebnis | Heidenheim (ots) - - Erfolgreiches 1. Halbjahr: Umsatzerlöse steigen auf 1.252,0 Mio. EUR, organisches Umsatzwachstum von 3,3 %; bereinigtes EBITDA liegt mit 151,7 Mio. EUR um 25,9 Mio. EUR über Vorjahreswert-... ► Artikel lesen | |
| CERENOME | 1,504 | +10,43 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| CARDINAL HEALTH | 212,80 | -0,19 % | Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | ||
| INMODE | 12,410 | -1,12 % | InMode Ltd.: InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 | YOKNEAM, Israel, Aug. 5, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,180 | +0,93 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen |